Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Archives of Psychiatry and Clinical Neuroscience
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 1/2014

01.11.2014 | Review

Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis

verfasst von: Hendrik Müller, Sonja Laier, Andreas Bechdolf

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of psychotherapy among individuals at clinical high risk (CHR) for psychosis is to prevent transition to full-blown psychosis. Psychotherapy in individuals with a first-episode psychosis (FEP) aims to reduce relapse rates. Remission of (pre-) psychotic symptoms, psychosocial functioning, quality of life, comorbid disorders and self-esteem are also important outcomes in individuals at CHR and with FEP. Antipsychotics, Qmega-3-Fatty acids and psychotherapy have been found to be effective in CHR for most of these aims. Thereby psychotherapy presents a better benefit/risk ratio than antipsychotic medication. The most evidence-based intervention is cognitive-behavioral therapy (CBT). Psychotherapy is mostly offered to FEP patients within specialized early intervention services (including assertiveness community treatment and antipsychotic medication). Thereby, CBT is effective for positive symptoms and family intervention is particularly effective for the prevention of relapses. We introduce the principles of CBT for psychosis and suggest adaptions for individuals at CHR and FEP. We conclude that the needs of young people at CHR and with FEP are best met by specially designed, low threshold outpatient clinical services, which include intensive psychotherapy treatment. A number of countries have implemented early detection and intervention services based on this model, while the implementation within in Germany is still marginal.
Literatur
1.
Whiteford HA, Degenhardt L, Rehm J et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586PubMedCrossRef
2.
Konnopka A, Klingberg S, Wittorf A et al (2009) [The cost of schizophrenia in Germany: a systematic review of the literature]. Psychiatr Prax 36:211–218PubMedCrossRef
3.
4.
Adams EK, Breen N, Joski PJ (2007) Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and Pap test utilization among white, Hispanic, and African American women: 1996–2000. Cancer 109:348–358PubMedCrossRef
5.
Peters AL, Davidson MB, Schriger DL et al (1996) A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the diagnosis of diabetes using glycated hemoglobin levels. J Am Med Assoc 276:1246–1252CrossRef
6.
Psaty BM, Lumley T, Furberg CD et al (2003) Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J Am Med Assoc 289:2534–2544CrossRef
7.
Häfner H, Riecher-Rossler A, Maurer K et al (1992) First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci 242:109–118PubMedCrossRef
8.
Häfner H, Maurer K, An der Heiden W (2013) ABC Schizophrenia study: an overview of results since 1996. Soc Psychiatry Psychiatr Epidemiol 48:1021–1031PubMedCrossRef
9.
Fusar-Poli P, Borgwardt S, Bechdolf A et al (2013) the psychosis high-risk state a comprehensive state-of-the-art review psychosis high-risk state. JAMA Psychiatry 70:107–120PubMedCrossRef
10.
Marshall M, Lewis S, Lockwood A et al (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 62:975–983PubMedCrossRef
11.
12.
Schultze-Lutter F, Ruhrmann S, Fusar-Poli P et al (2012) Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des 18:351–357PubMedCrossRef
13.
Yung AR, Phillips LJ, Yuen HP et al (2003) Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res 60:21–32PubMedCrossRef
14.
Broome MR, Woolley JB, Johns LC et al (2005) Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry 20:372–378PubMedCrossRef
15.
Carr V, Halpin S, Lau N et al (2000) A risk factor screening and assessment protocol for schizophrenia and related psychosis. Aust N Z J Psychiatry 34(Suppl):S170–S180PubMedCrossRef
16.
Cornblatt BA, Lencz T, Smith CW et al (2003) The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 29:633–651PubMedCrossRef
17.
McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799PubMedCrossRef
18.
Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251PubMedCrossRef
19.
Simon AE, Dvorsky DN, Boesch J et al (2006) Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res 81:83–90PubMedCrossRef
20.
Yung AR, Stanford C, Cosgrave E et al (2006) Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 84:57–66PubMedCrossRef
21.
22.
Klosterkotter J, Hellmich M, Steinmeyer EM et al (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158–164PubMedCrossRef
23.
24.
Fusar-Poli P, Nelson B, Valmaggia L et al (2014) Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull 40:120–131PubMedCrossRefPubMedCentral
25.
26.
Bechdolf A, Pukrop R, Kohn D et al (2005) Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res 79:137–143PubMedCrossRef
27.
Lencz T, Smith CW, Auther A et al (2004) Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res 68:37–48PubMedCrossRef
28.
Velthorst E, Nieman DH, Linszen D et al (2010) Disability in people clinically at high risk of psychosis. Br J Psychiatry 197:278–284PubMedCrossRef
29.
30.
Ziermans TB, Schothorst PF, Sprong M et al (2011) Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res 126:58–64PubMedCrossRef
31.
Fusar-Poli P, Deste G, Smieskova R et al (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69:562–571PubMed
32.
Giuliano JA, Li H, Mesholam-Gately IR et al (2012) Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des 18:399–415PubMedCrossRef
33.
Phillips LJ, Velakoulis D, Pantelis C et al (2002) Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr Res 58:145–158PubMedCrossRef
34.
Velakoulis D, Wood SJ, Wong MT et al (2006) Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63:139–149PubMedCrossRef
35.
Yücel M, Wood SJ, Phillips LJ et al (2003) Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. Br J Psychiatry 182:518–524PubMedCrossRef
36.
Stone JM, Day F, Tsagaraki H et al (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 66:533–539PubMedCrossRef
37.
Fusar-Poli P, Howes O, Allen P et al (2009) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16:67–75PubMedCrossRef
38.
Fusar-Poli P, Howes OD, Allen P et al (2010) Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 67:683–691PubMedCrossRef
39.
Fusar-Poli P, Stone JM, Broome MR et al (2011) Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 68:881–890PubMedCrossRef
40.
McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799PubMedCrossRef
41.
McGorry P, Nelson B, Phillips L et al (2012) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. doi:10.​4088/​JCP.​12m07785
42.
McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928PubMedCrossRef
43.
Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154PubMedCrossRef
44.
Addington J, Epstein I, Liu L et al (2011) A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 125:54–61PubMedCrossRef
45.
Morrison AP, French P, Stewart SL et al (2012) Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 344:e2233PubMedCrossRefPubMedCentral
46.
Morrison AP, French P, Walford L et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 185:291–297PubMedCrossRef
47.
van der Gaag M, Nieman DH, Rietdijk J et al (2012) Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 38:1180–1188CrossRefPubMedCentral
48.
Bechdolf A, Wagner M, Ruhrmann S et al (2012) Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 200:22–29PubMedCrossRef
49.
Nordentoft M, Thorup A, Petersen L et al (2006) Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 83:29–40PubMedCrossRef
50.
Miklowitz DJ, O’Brien MP, Schlosser DA et al (2014) Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. doi:10.​1016/​j.​jaac.​2014.​04.​020
51.
52.
van der Gaag M, Smit F, Bechdolf A et al (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 149:56–62PubMedCrossRef
53.
Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145–153PubMedCrossRef
54.
Angermeyer MC, Matschinger H, Schomerus G (2013) Attitudes towards psychiatric treatment and people with mental illness: changes over two decades. Br J Psychiatry 203:146–151PubMedCrossRef
55.
Lauber C, Nordt C, Falcato L et al (2001) Lay recommendations on how to treat mental disorders. Soc Psychiatry Psychiatr Epidemiol 36:553–556PubMedCrossRef
56.
Morrison AP, Birchwood M, Pyle M et al (2013) Impact of cognitive therapy on internalised stigma in people with at-risk mental states. Br J Psychiatry 203:140–145PubMedCrossRef
57.
Association AP (2006) American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006. Am Psychiatric Pub, Washington
58.
Birchwood M, Fiorillo A (2000) The critical period for early intervention. Psychiatric Rehabil Skills 4:182–198CrossRef
59.
Boonstra N, Klaassen R, Sytema S et al (2012) Duration of untreated psychosis and negative symptoms—a systematic review and meta-analysis of individual patient data. Schizophr Res. doi:10.​1016/​j.​schres.​2012.​08.​017
60.
Barnes TR, Leeson VC, Mutsatsa SH et al (2008) Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry 193:203–209PubMedCrossRefPubMedCentral
61.
Perkins DO, Gu H, Boteva K et al (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162:1785–1804PubMedCrossRef
62.
Harrigan SM, McGorry P, Krstev H (2003) Does treatment delay in first-episode psychosis really matter? Psychol Med 33:97–110PubMedCrossRef
63.
Penttilä M, Jääskeläinen E, Hirvonen N et al (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205:88–94PubMedCrossRef
64.
Addington J, Leriger E, Addington D (2003) Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry 48:204–207PubMed
65.
Lieberman JA, Phillips M, Gu H et al (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. doi:10.​1038/​sj.​npp.​1300157
66.
Coldham E, Addington J, Addington D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106:286–290PubMedCrossRef
67.
Schennach-Wolff R, Jäger M, Seemüller F et al (2009) Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res 43:1294–1301PubMedCrossRef
68.
Robinson D, Woerner MG, Alvir JMJ et al (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241–247PubMedCrossRef
69.
Watt DC, Katz K, Shepherd M (1983) The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 13:663–670PubMedCrossRef
70.
Melle I, Johannesen J, Friis S et al (2006) Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 163:800–804PubMedCrossRef
71.
Birchwood M (2003) Pathways to emotional dysfunction in first-episode psychosis. Br J Psychiatry 182:373–375PubMedCrossRef
72.
Wisdom JP, Manuel JI, Drake RE (2011) Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatric Serv 62:1007–1012CrossRef
73.
Bechdolf PDA, Pohlmann B, Güttgemanns J et al (2012) Motivationsbehandlung für Patienten mit der Doppeldiagnose Psychose und Sucht. Der Nervenarzt 83:888–896PubMedCrossRef
74.
Elkins K, Hinton M, Edwards J (2004) Cannabis and psychosis: a psychological intervention. In: Gleeson JFM, McGorry PD (eds) Psychological interventions in early psychosis. Wiley, Chichester, p 137–156. ISBN: 0470020636, 9780470020630
75.
Meister K, Burlon M, Rietschel L et al (2010) Psychose und Sucht bei Jugendlichen und Jungerwachsenen BR Teil 1: Prävalenz und Erklärungsmodelle. Fortschritte der Neurologie Psychiatrie 78:81–89PubMedCrossRef
76.
Álvarez-Jiménez M, Parker AG, Hetrick SE et al (2011) Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 37:619–630PubMedCrossRefPubMedCentral
77.
Bird V, Premkumar P, Kendall T et al (2010) Early intervention services, cognitive–behavioural therapy and family intervention in early psychosis: systematic review. Br J Psychiatry 197:350–356PubMedCrossRefPubMedCentral
78.
79.
Nuechterlein KH, Dawson ME (1984) A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 10:300–312PubMedCrossRef
80.
Larsen TK, Bechdolf A, Birchwood M (2003) The concept of schizophrenia and phase-specific treatment: cognitive-behavioral treatment in pre-psychosis and in nonresponders. J Am Acad Psychoanal Dyn Psychiatry 31:209–228PubMedCrossRef
81.
Garety PA, Kuipers E, Fowler D et al (2001) A cognitive model of the positive symptoms of psychosis. Psychol Med 31:189–195PubMedCrossRef
82.
Cantor-Graae E, Selten JP (2005) Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry 162:12–24PubMedCrossRef
83.
Matheson SL, Shepherd AM, Pinchbeck RM et al (2013) Childhood adversity in schizophrenia: a systematic meta-analysis. Psychol Med 43:225–238PubMedCrossRef
84.
85.
86.
Fine C, Gardner M, Craigie J et al (2007) Hopping, skipping or jumping to conclusions? Clarifying the role of the JTC bias in delusions. Cogn Neuropsychiatr 12:46–77CrossRef
87.
Morris EMJ, Johns LC, Oliver JE (2013) Acceptance and commitment therapy and mindfulness for psychosis. Wiley, LondonCrossRef
88.
Kingdon DG, Turkington D (2005) Cognitive therapy of schizophrenia [electronic resource]. Guilford Publications, Incorporated, New York
89.
Lieberman JA, Fenton WS (2000) Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 157:1727–1730PubMedCrossRef
90.
Henry L (2002) Cognitively oriented psychotherapy for first episode psychosis (COPE): a practitioner’s manual: early psychosis prevention and intervention centre. ISBN: 192071801X
91.
Herrmann-Doig T, Maude D, Edwards J (2002) Systematic Treatment of Persistent Psychosis (STOPP): a psychological approach to facilitating recovery in young people with first-episode psychosis. Taylor & Francis, LondonCrossRef
92.
French P, Morrison AP (2004) Early detection and cognitive therapy for people at high risk of developing psychosis: a treatment approach. Wiley, LondonCrossRef
93.
Müller H, Bechdolf A (2013) Ist eine Behandlung mit Antipsychotika gerechtfertigt? InFo Neurologie & Psychiatrie 15:38–42CrossRef
94.
McGlashan TH, Levy ST, Carpenter WT Jr (1975) Integration and sealing over: clinically distinct recovery styles from schizophrenia. Arch Gen Psychiatry 32:1269PubMedCrossRef
95.
Gleeson JFM, McGorry PD (2004) Psychological interventions in early psychosis: a treatment handbook. Wiley, London
96.
Taylor SE (1983) Adjustment to threatening events: a theory of cognitive adaptation. Am Psychol 38:1161CrossRef
97.
98.
Häfner HBA, Klosterkötter J, Maurer K (2012) Psychosen - Früherkennung und Frühintervention. Der Praxisleitfaden. Schattauer, Stuttgart
99.
100.
Birchwood M, Connor C, Lester H et al (2013) Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br J Psychiatry 203:58–64PubMedCrossRef
101.
NICE. National Institute for Health and Clinical Excellence Schizophrenia (2009) Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Institute for Health and Clinical Excellence, London
102.
Phillips LJ, Cotton S, Mihalopoulos C et al (2009) Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Interv Psychiatry 3:28–34PubMedCrossRef
103.
Valmaggia LR, McCrone P, Knapp M et al (2009) Economic impact of early intervention in people at high risk of psychosis. Psychol Med 39:1617–1626PubMedCrossRef
104.
Bechdolf A, Muller H, Stutzer H et al (2011) Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophr Bull 37(Suppl 2):S111–S121PubMedCrossRefPubMedCentral
105.
Häfner H, Bechdolf A, Klosterkötter J et al. Psychosen - Früherkennung und Frühintervention: Der Praxisleitfaden: Schattauer; 2012
Metadaten
Titel
Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis
verfasst von
Hendrik Müller
Sonja Laier
Andreas Bechdolf
Publikationsdatum
01.11.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe Sonderheft 1/2014
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-014-0538-0

Weitere Artikel der Sonderheft 1/2014

European Archives of Psychiatry and Clinical Neuroscience 1/2014 Zur Ausgabe

Original Paper

Interaction among childhood trauma and functional polymorphisms in the serotonin pathway moderate the risk of depressive disorders

Review

Multistage drug effects of ketamine in the treatment of major depression

Review

A perfect match: noninvasive brain stimulation and psychotherapy

Review

Prediction and prevention of psychosis: current progress and future tasks

Review

Antipsychotic treatment modulates glutamate transport and NMDA receptor expression

Review

Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD)

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise